HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.
Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.
The U.S. Food and Drug Administration (FDA) this week approved 2 new fixed-dose coformulations of HIV protease inhibitors with a cobicistat booster. Bristol-Myers Squibb's Evotaz contains atazanavir (sold separately as Reyataz) plus cobicistat, while Janssen Therapeutics' Prezcobix contains darunavir (sold separately as Prezista) plus cobicistat.
Truvada (tenofovir/emtricitabine) used for pre-exposure prophylaxis (PrEP) was not associated with clinically relevant declines in kidney function through 36 months in a large clinical trial, researchers recently reported. A related study found that drug resistance is rare among PrEP users, but it can occur in people who have acute HIV infection when they start Truvada and those who become infected despite PrEP.
Elite controllers -- people who naturally maintain viral suppressed without antiretroviral treatment -- had higher rates of hospitalization than people with HIV on antiretroviral therapy, most commonly for cardiovascular conditions, researchers reported in the December 15 Journal of Infectious Diseases. A related study showed that B cell follicles may act as a reservoir for an HIV-like virus in elite controller monkeys.